We demonstrated the therapeutic value of BPTF in a mouse model of PDA driven by the c-MYC oncogene (Ela1-Myc) [20]; however, the main limitation of this study was the use of the pancreatic cancer mouse model, where tumorigenesis was driven by the c-MYC oncogene instead of KRAS, the main driver mutation in PDA [32]. This evidence concerns the gene KRAS and Patent ductus arteriosus.